Neuronetics Brightens Outlook For Neuro Devices
Executive Summary
Neuronetics Inc. forged a new specialty of sorts, the interventional psychiatrist. Unlike other interventional approaches, the externally applied NeuroStar delivers transcranial magnetic stimulation to the precise area of the brain responsible for intractable depression. The device is changing the lives of psychiatrists who launched “TMS” clinics, hoping to capture the early success, and potentially creating opportunities for medical devices designed to treat other brain-related disorders.
You may also be interested in...
Research Briefs: Study Updates From Neuronetics, Edwards
Neuronetics starts study enrollment for its NeuroStar transcranial magnetic stimulation to treat postpartum depression. Edwards delays enrollment for Sapien XT Cohort A of the PARTNER II trial. More research news.
Device Start-Ups Inch Closer To Elusive Epilepsy Treatment
Despite the availability of more than 20 anti-epilepsy drugs, surgery, and a neurostimulation therapy that’s been available for 15 years, a large proportion of the three million patients in the US with epilepsy continue to have seizures. Emerging device companies aim to provide a solution for them.
Brainsway Closes Gap Between Devices And Drugs With Noninvasive Deep Brain Stimulation
Following a series of private investments and strategic acquisitions, Brainsway Ltd. announced it had received CE mark approval for a new therapy for chronic neuropathic pain, bringing another potential neurostimulation treatment to market in Europe. Meanwhile, the company reported positive interim results on its clinical trial of a treatment for obsessive compulsive disorder, adding to positive results from a pivotal multicenter trial studying its therapy for major depression. These trials validate a new device treatment for conditions that neurologists and psychiatrists typically treat with drugs.